Related Experiment Video
Updated: May 20, 2025
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
The Role of SBDP Protein as a Potential Biomarker for Early-Onset Subarachnoid Hemorrhagic
Ita M Sari1,2, Selfy Oswari1,2, Paulus A Ong3
1Doctoral Program in Medical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Insights
Spectrin degradation products (SBDPs) show promise as biomarkers for subarachnoid hemorrhage (SAH). Elevated SBDP145 levels can predict vasospasm risk, while SBDP145 and SBDP120 predict poor functional outcomes in SAH patients.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Clinical Chemistry
Background:
- Cerebral vasospasm is a common, high-mortality complication of subarachnoid hemorrhage (SAH).
- Current early biomarkers for predicting SAH complications and outcomes are limited.
- Spectrin degradation products (SBDPs) are investigated as potential novel biomarkers.
Purpose of the Study:
- To analyze SBDP150, SBDP145, and SBDP120 levels in SAH patients.
- To assess SBDPs as potential biomarkers for predicting vasospasm and functional outcomes (Glasgow Outcome Scale-Extended, GOSE).
- To monitor clinical outcomes in SAH patients using SBDPs.
Main Methods:
- Prospective observational study of acute SAH patients within 72 hours of onset.
- Cerebrospinal fluid (CSF) collected via continuous cerebrospinal drainage (lumbar drainage or extraventricular drainage).
- ELISA used to measure SBDP levels; Friedman and Wilcoxon analyses applied to assess changes and group differences.
Main Results:
- Significant temporal changes observed for SBDP120 and SBDP145, but not SBDP150.
- Higher SBDP120 and SBDP145 levels noted in the extraventricular drainage group compared to lumbar drainage group.
- SBDP145 on day 5 predicted vasospasm risk; SBDP145 and SBDP120 on day 7 predicted poor functional outcomes (GOSE at 90 days).
Conclusions:
- Elevated SBDP145 on day 5 may indicate vasospasm risk in SAH patients.
- Increased SBDP145 and SBDP120 levels on day 7 are potential predictors of unfavorable functional outcomes.
- SBDPs demonstrate potential as valuable biomarkers for managing SAH and its complications.
Abstract:
Background and Objectives: Cerebral vasospasm is the most common complication of subarachnoid hemorrhage (SAH) that is related to high mortality and morbidity. Early biomarkers predicting those conditions are still limited. This study aims to analyze spectrin degradation products (SBDPs) as potential biomarkers for SAH patients, which can be used to monitor clinical outcomes. Materials and Methods: We conducted a prospective observational study in acute SAH within 72 h of onset. All patients underwent placement of continuous cerebrospinal drainage, and liquor was taken four times and analyzed using ELISA to measure SBDP150, SBDP145, and SBDP120 levels and analyzed using Friedman test and post hoc Wilcoxon analysis. The relationship between SBDP levels and vasospasm, as well as functional outcomes (using the Glasgow Outcome Scale-Extended, GOSE), was assessed. Results: We enrolled thirty-five patients: thirty patients with lumbar drainage (LD) and five with extra ventricular drainage (EVD). Friedman's analysis showed significant changes over time for SBDP120 (p = 0.0001) and SBDP145 (p = 0.0001), but not for SBDP150 (p = 0.218). Levels of SBDP120 on day 3 (p = 0.001), SBDP120 on day 5 (p = 0.022), and SBDP145 on day 3 (p = 0.005) in EVD group were higher than in the LD group. SBDP145 on day 5 was significantly higher in patients with vasospasm (p = 0.041 in all patients, p = 0.028 in LD patients), indicating its potential as an early biomarker for vasospasm. SBDP145 on day 7 (p = 0.014) is the strongest predictor of unfavorable GOSE at 90 days in all patients. In LD patients, SBDP145 on day 7 (p = 0.002), SBDP120 on day 7 (p = 0.009), and SBDP120 on day 10 (p = 0.043) were significantly associated with poor GOSE at 90 days. Conclusions: A higher level of SBDP145 on day 5 can predict vasospasm risk, while an elevated level of SBDP145 and SBDP120 on day 7 is a potential predictor of poor functional outcomes. SBDPs may serve as valuable biomarkers for SAH management.
